Zimmer Biomet Holdings, Inc. Securities Lawsuit Investigation

Shamis & Gentile P.A., a law firm that advocates for investors who are victims of securities fraud, is investigating potential claims against Zimmer Biomet Holdings, Inc. (ZBH)

If you purchased or otherwise acquired Zimmer Biomet Holdings securities between February 2025 and November 4, 2025, and suffered losses, you may be eligible to join this securities investigation and seek compensation.

About Zimmer Biomet Holdings

Zimmer Biomet Holdings is a global medical-device company that develops, manufactures, and markets orthopedic reconstructive, spinal, and trauma products as well as related surgical technologies.

The company operates internationally with major markets in the United States, Latin America, Eastern Europe, and the Middle East.

Potential Concerns Under Investigation

Attorneys are reviewing whether Zimmer Biomet Holdings and certain executives made false or misleading statements or failed to disclose material information between February 6, 2025, and November 4, 2025, regarding the company’s financial performance, regional demand, and growth outlook.

The investigation covers a series of public statements throughout 2025. On February 6, 2025, Zimmer Biomet reported a 4.3% sales increase and reaffirmed full-year guidance, saying it was “delivering on our financial guidance” while highlighting expansion into higher-growth areas.

Three months later, on May 5, 2025, management characterized first-quarter results as “solid,” citing “momentum in U.S. Hips.” The company nonetheless lowered earnings guidance to reflect acquisition and tariff impacts but maintained a broadly optimistic tone that downplayed potential headwinds.

By August 7, 2025, the company again described results as “solid” and pointed to a “robust new product cycle.” Zimmer Biomet raised full-year EPS guidance due to lower-than-expected tariff costs yet only narrowed its revenue range, suggesting caution about demand trends. Within one quarter, that optimism faded.

However, on November 5, 2025, Zimmer Biomet reported third-quarter net sales of about $2 billion, slightly below consensus estimates, and reduced the top end of its full-year organic revenue growth forecast from 4.5% to 4.0%. The company cited weakness in Latin America, Eastern Europe, and the Middle East, as well as a $24 million to $25 million hit from a last-minute distributor order cancellation.

Following these disclosures, Zimmer Biomet’s stock declined roughly 15% in a single day, from closing at $103.18 on November 4, 2025 to $87.55 on November 5, resulting in substantial losses for investors.

Lawyers are evaluating whether Zimmer Biomet’s earlier public statements accurately reflected known challenges in international operations and whether investors were adequately warned about distributor exposure and demand volatility before the corrective disclosure.

Your Rights and Next Steps

This is an ongoing investigation and not a filed lawsuit. Investors who purchased or otherwise acquired Zimmer Biomet Holdings securities during the relevant period, and suffered losses may have legal rights. If evidence shows that investors were misled, the case could lead to a class-action lawsuit to recover damages for affected shareholders.

Lawyers are available to help investors review their options and determine whether they qualify to participate. There is no cost or obligation to join the investigation, and participation is confidential.

You May Be Entitled to Compensation

Securities investigations are time-sensitive, and acting promptly can help preserve your rights. If you purchased or otherwise acquired Zimmer Biomet Holdings securities during the relevant period, you may be eligible to seek compensation for your losses.

To protect your rights and participate in this investigation, complete the form below.